Effect of three different liposomal eye sprays on ocular comfort and tear film

Pult, Heiko; Gill, Felicity R.; Riede-Pult, Britta

doi:10.1016/j.clae.2012.05.003

Cited by 21 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The success of topically administered ocular liposomes has been attributed to the increased residence time of the formulation, [128,133,140,141] to the gradual release of the drug at the ocular surface [77,142,143] and to the decrease in toxic side effects of the drug compared with typical eye drops containing the same drug. [47] The gradual drug release is attributed to the interactions between the drug and the liposomes, [93] but the increase in ocular surface residence time is particularly correlated with the liposome zeta potential and the affinity of the liposome for the corneal surface.…”

Section: Liposomesmentioning

confidence: 99%

“…Another very useful and typical approach is the association of polymers with the liposome surface. [51,140,154] This strategy not only improves the liposome stability but also changes and adjusts the surface charge of the liposomes. For instance, diclofenac-loaded liposomes composed of 1,2-distearoylsn-glycero-3-phosphocholine and cholesterol were prepared by the calcium acetate gradient method.…”

Section: Liposomesmentioning

confidence: 99%

“…The Author(s) declare(s) that they have no conflicts of interest to disclose. [33,35,42,44,46,52,54,69,115,117,133,134,138,141,142,201,208,245,254,260] Chronic dry eye Nanoemulsions, liposomes, solid lipid nanoparticles, microemulsions, iontophoresis [14,27,35,48,115,140,259] Glaucoma Nanoemulsions, liposomes, solid lipid nanoparticles, microemulsions, hydrogels, contact lenses, polymeric nanoparticles, dendrimer, iontophoresis, sonophoresis [27,30,31,41,43,55,88,91,94,95,107,132,135,168,172,199,[270][271][272][273][274][275] Choroidal neovascularisati...…”

Section: Conflict Of Interestmentioning

confidence: 99%

See 2 more Smart Citations

Topical delivery of ocular therapeutics: carrier systems and physical methods

Souza

Dias

Pereira

et al. 2013

Journal of Pharmacy and Pharmacology

114

View full text Add to dashboard Cite

Objective The basic concepts, major mechanisms, technological developments and advantages of the topical application of lipid-based systems (microemulsions, nanoemulsions, liposomes and solid lipid nanoparticles), polymeric systems (hydrogels, contact lenses, polymeric nanoparticles and dendrimers) and physical methods (iontophoresis and sonophoresis) will be reviewed. Key findings Although very convenient for patients, topical administration of conventional drug formulations for the treatment of eye diseases requires high drug doses, frequent administration and rarely provides high drug bioavailability. Thus, strategies to improve the efficacy of topical treatments have been extensively investigated. In general, the majority of the successful delivery systems are present on the ocular surface over an extended period of time, and these systems typically improve drug bioavailability in the anterior chamber whereas the physical methods facilitate drug penetration over a very short period of time through ocular barriers, such as the cornea and sclera. Summary Although in the early stages, the combination of these delivery systems with physical methods would appear to be a promising tool to decrease the dose and frequency of administration; thereby, patient compliance and treatment efficacy will be improved.

show abstract

Section: Liposomesmentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

Section: Conflict Of Interestmentioning

confidence: 99%

See 1 more Smart Citation

Topical delivery of ocular therapeutics: carrier systems and physical methods

Souza

Dias

Pereira

et al. 2013

Journal of Pharmacy and Pharmacology

114

View full text Add to dashboard Cite

show abstract

“…The stabilizing effect of LS for the treatment of dry eye has been confirmed in several studies [7-12]: In a prospective randomized double-masked investigation, Craig et al [7] reported significant improvements in lipid characteristics, such as tear film stability and lipid layer thickness as well as improved comfort, in patients after the application of LS. Furthermore, results of prospective controlled open studies show that liposomes can be applied as a nasal spray and thus can be successfully used to treat rhinitis symptoms [13-15]: Similar to the effect on the conjunctiva, the liposomes integrate into the destabilized “nasal surfactant” and stabilize the natural moisture film [16].…”

Section: Introductionmentioning

confidence: 93%

“…Overall, previous results from prospective, controlled studies (some of which were randomized and blinded or open-label) suggest that liposomes, in particular in the form of an eye spray, are a promising alternative to standard drug therapy for treating allergic symptoms and should be investigated further [6-12]. Consequently, it was the objective of the present study to gain information on how stabilization of the tear film can influence eye symptoms/irritation during natural allergen exposure in the allergy season.…”

Section: Introductionmentioning

confidence: 99%

Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

Grzella

Schleicher

Shah‐Hosseini

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Liposomal eye spray (LS) has been introduced for the treatment of dry eye. Whether LS can also relieve symptoms due to allergic rhinoconjunctivitis (ARC) has not yet been sufficiently investigated. Objectives: The aim of this study was to assess the onset of action, the reduction of allergy symptoms, and the safety of LS – a nonpharmacological treatment option – compared with those of antihistamine eye drops (AD). Methods: In this open, prospective, controlled, monocenter noninterventional study, adults with ARC received either LS or AD for the relief of eye irritation after a positive conjunctival provocation test (CPT). All patients completed a questionnaire before and after the CPT. Eye irritation was rated on a visual analogue scale (VAS) at 6 time points. Conjunctival redness was analyzed using objective digital analysis based on images taken during the study visit. Results: Data were collected from 40 patients (20 per group). In both groups, 80% of patients perceived an onset of action within 0–2 min after application of LS or AD following the CPT. Relief of eye irritation (as determined by VAS) increased throughout the visit for both groups. In the digital analysis, the mean proportion of redness of the eye decreased from 10.3 to 7.0% for LS and from 10.4 to 6.5% for AD, with the largest difference observed 10 min after application (LS: 8.9%; AD: 6.0%; p = 0.094). Conclusions: LS is a nonpharmacological treatment option for ARC, showing no significant difference or relevant numerical inferiority to AD in any parameter studied. It was generally safe and well tolerated.

show abstract

Over the counter (OTC) artificial tear drops for dry eye syndrome

Pucker

Nichols

2016

Cochrane Database of Systematic Reviews

123

124

View full text Add to dashboard Cite

Background-Over the counter (OTC) artificial tears historically have been the first line of treatment for dry eye syndrome and dry eye-related conditions like contact lens discomfort, yet currently we know little regarding the overall efficacy of individual, commercially available artificial tears. This review provides a much needed meta-analytical look at all randomized and quasi-randomized clinical trials that have analyzed head-to-head comparisons of OTC artificial tears. Objectives-To evaluate the effectiveness and toxicity of OTC artificial tear applications in the treatment of dry eye syndrome compared with another class of OTC artificial tears, no treatment, or placebo. Search methods-We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2015, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to December 2015), EMBASE (January 1980 to December 2015), Latin American and Caribbean Health Sciences (LILACS) (January 1982 to December 2015), the ISRCTN registry (www.isrctn.com/ editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en)

show abstract

Effect of three different liposomal eye sprays on ocular comfort and tear film

Cited by 21 publications

References 19 publications

Topical delivery of ocular therapeutics: carrier systems and physical methods

Topical delivery of ocular therapeutics: carrier systems and physical methods

Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

Over the counter (OTC) artificial tear drops for dry eye syndrome

Contact Info

Product

Resources

About